

INFANTILE SPASMS


Little Seizures: Big Consequences



Infantile spasms (IS) is a rare **seizure disorder** occurring in just **1 out of 2000 children under two years old**. Prompt diagnosis and accurate treatment of IS are critical to provide optimal developmental outcomes for these young children.

THE NEED FOR AWARENESS

Most pediatricians will only encounter 1 or 2 IS cases throughout all their years of medical practice



Lack of exposure to IS results in delays of accurate diagnosis and appropriate treatment

IS is frequently misdiagnosed as

Colic Normal startle reflex Reflux


WHEN LEFT UNTREATED IS MAY CAUSE

CONFIRM THE INFANTILE SPASMS DIAGNOSIS

ELECTROENCEPHALOGRAMS (EEGs)

STUDY THE ELECTRICAL ACTIVITY OF BRAIN WAVES:

An EEG from a qualified child neurologist should be done on every child suspected of having IS



FINDING THE PATTERN:

Normal EEGs show an **organized pattern** of brain waves with clear separation between each electrical signal

1. Hypsarrhythmia has a very high-voltage, disorganized pattern of brain waves



2. Modified hypsarrhythmia is a less chaotic pattern of hypsarrhythmia

3. Electrodecremental response: EEG typically "flattens out" for a very brief time

Many patients with IS will have all three patterns

Though causes of IS are countless, 70% of underlying IS causes can be identified with careful evaluation

FIND THE CAUSE TO DETERMINE TREATMENT

BRAIN ABNORMALITIES OR INJURIES

Lack of oxygen

INFECTION

Meningitis

Encephalitis

DISORDERS

Tuberous sclerosis complex (TSC)

Dravet syndrome

IS IDENTIFICATION

Symptomatic

- Cases where neurologists are able to identify the cause of IS

- Specific treatments can be recommended

- Some underlying causes of IS do not allow for a child to develop normally even if the spasms are completely controlled


Cryptogenic

- Cases of IS where the cause can not be identified

- That is prompt and successful can allow a child with cryptogenic IS to develop normally



Common cause: 1/3 of children with TSC are also affected by IS



TREATMENT OF INFANTILE SPASMS: THERE IS HOPE!



IS THERAPY'S GOAL IS TO ACHIEVE COMPLETE CONTROL OF THE SPASMS

IS must be diagnosed early and treated accurately

Some children with IS will lead normal lives

PROPER TREATMENT WILL

✓ Stop seizures

✓ Eliminate hypsarrhythmia

✓ Be associated with developmental recovery



The American Academy of Neurology and Child Neurology Society treatment guidelines specify that **successful treatment** must stop both spasms and hypsarrhythmia

Only 2 drugs are approved by the FDA for the treatment of IS

• Adrenocorticotropic hormone (ACTH)

• Vigabatrin

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

ACTH MARKETED AS ACTHAR® GEL

Used to treat IS since 1958—Approved by the FDA in 2010

Precise mechanism by which the ACTH hormone acts on IS is unknown. More likely to be effective at higher doses than lower doses. Spasms may return in some children when the medication has been tapered and stopped

POTENTIAL SIDE EFFECTS

Less serious side effects

- Extreme hunger and weight gain

- High irritability

More serious side effects

- High blood pressure

- Decreased glucose levels in the blood

- Stomach ulcer

- Slowed growth

- Heart problems

- Immunosuppression (difficulty fighting infection)

- Decreased muscle tone

- Sleepiness

- Difficulty sleeping

High dose treatment + shortest duration possible =

Best chance for controlling the spasms with less risk of serious complications

Potential side effects

- Decreased muscle tone

- Sleepiness

- Difficulty sleeping

VIGABATRIN MARKETED AS SABRIL®

Used to treat IS since 1991—approved by the FDA in 2009

Acts by increasing the amount of GABA (an inhibitory brain signaling molecule) in the brain. The 2012 International TSC Consensus Conference recommends vigabatrin as first-line therapy for patients who have IS associated with TSC

POTENTIAL SIDE EFFECTS

Less serious side effects

- Decreased muscle tone

- Sleepiness

- Difficulty sleeping

More serious side effects

- Potential for visual field constriction (tunnel vision)

- Blindness has not been reported and central vision appears to be unaffected

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

PREDNISOLONE AT HIGH DOSES FOR SHORT DURATIONS

- Alternative to the use of ACTH

- Can be given orally whereas ACTH requires daily injections

CHILD NEUROLOGISTS MAY DISCUSS THE USE OF ADDITIONAL TREATMENT OPTIONS TO HELP MANAGE IS AND ITS EFFECTS

- Vitamin B6 (pyridoxine) or Pyridoxal-5

- Zonisamide

- Clonazepam

- Clazosam

- Valproic acid

PROPER TREATMENT WILL

✓ Stop seizures

✓ Eliminate hypsarrhythmia

✓ Be associated with developmental recovery

ADDITIONAL TREATMENT OPTIONS

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS

The decision to treat initially with ACTH or vigabatrin is made by a child neurologist in consultation with the caregiver(s)

EACH TREATMENT DECISION IS UNIQUE BASED ON EACH CHILD'S PRESENTATION OF IS</